Molecular engineering of gene therapies for the nervous system
DNA as medicine
Historical timeline in molecular medicine development
started with small molecules (1908 start)
Protein therapies (1920s start)
gene therapies (1980s had some therapies that were somewhat effective)
Stem cells (1960s start)
More chronic health conditions are now the problems.
Chronic age related disease
alzheimers, parkinsons, etc…
Three problems of gene therapy – delivery, delivery and delivery
Adeno associated virus (5 kilobases – AAV)
60 units of CAP protein assemble to form icosahedral capsid
numerous natural variants have been isolated
Highly safe 90% of human population exposed to AAV
recent success curing gene based blindness
fixing Leber’s congenital amaurosis
success against hemophilia B
Taking care of rare monogenetic disease to gain momentum
Derisk the therapies
Lipoprotein lipase deficiency (AAV)
Need better delivery vehicles.
pre-existing immunity to AAV
Each of the viruses have issues
Nature did not evolve viruses to be used as human therapies
Continual viral evolution to get the right properties for biomedical applications
Using directed evolution to make designer viruses for medical applications.
Inner limiting membrane – barrier to delivering genes against blindness or other eye problems
evolve virus to penetrate the inner limiting membrane
Retinoschisis (another eye disease)
work on mouse model to delivery treatment and rescue the retina
5 kilobases is the max payload size, they are working to engineer larger version of the virus.
There are also approaches to try to cutdown the size of the payload while maintaining effectiveness
Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million readers per month. His blog Nextbigfuture.com is ranked #1 Science News Blog. It covers many disruptive technology and trends including Space, Robotics, Artificial Intelligence, Medicine, Anti-aging Biotechnology, and Nanotechnology.
Known for identifying cutting edge technologies, he is currently a Co-Founder of a startup and fundraiser for high potential early-stage companies. He is the Head of Research for Allocations for deep technology investments and an Angel Investor at Space Angels.
A frequent speaker at corporations, he has been a TEDx speaker, a Singularity University speaker and guest at numerous interviews for radio and podcasts. He is open to public speaking and advising engagements.